Fast Market Research

New Market Study, "Pharmaceutical Business Confidence Report Q1 2014", Has Been Published

New Pharmaceuticals market report from Kable Market Intelligence: "Pharmaceutical Business Confidence Report Q1 2014"

 

Boston, MA -- (ReleaseWire) -- 02/07/2014 -- "Pharmaceutical Business Confidence Report Q1 2014" is a new report by Kable that analyzes pharmaceutical industry executives' views on the global economy, expectations on customer confidence, supplier prices, key business concerns, and how executives' future investments are set to change in Q1 2014. This report also gives you access to regional analysis of industry outlook, industry and company growth prospects, future opportunities, staff hiring, and sales performance. Apart from providing access to the opinions and strategies of global pharmaceutical industry executives, it also examines their actions surrounding business priorities, threats and opportunities, and future investment areas over the next six months. Moreover, this report provides a comparative analysis of survey results with Q4 2013 wherever applicable.

View Full Report Details and Table of Contents

Introduction and Landscape
Why was the report written?
This report is the result of an extensive survey drawn from Kable's exclusive panel of leading global pharmaceutical industry executives. The report analyzes current economic conditions prevailing across the globe and their impact on the pharmaceutical industry, and forecasts company and industry growth prospects over the next six months. Furthermore, it provides information about the impact of customer confidence, supplier prices, and staff headcount likely to affect the investment decisions of the industry over the next six months. Additionally, this report tracks the change in executives' perceptions during the last three months, by providing a comparative analysis of survey results with the previous quarter.

What is the current market landscape and what is changing?
Overall, 74% and 60% of global pharmaceutical industry executives are optimistic about the future growth prospects of both their company and the industry, respectively, over the next six months. Optimism towards company and industry growth prospects has improved by eight and ten percentage points, respectively, in Q1 2014, compared to Q4 2013 results.

What are the key drivers behind recent market changes?
Optimism towards industry and company growth is driven by the improving global economic conditions, investments in emerging markets, and the introduction of new products in the market.

What makes this report unique and essential to read?

Companies Mentioned in this Report: Merck Serono, Salix Pharmaceuticals, Santarus Inc., AstraZeneca, Pearl Therapeutics, GlaxoSmithKline

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Global Pharmaceutical Survey 2013-2014 - Market Trends, Buyer Spend and Procurement Strategies in the Global Pharmaceutical Industry
- Global Pharmaceutical Survey 2013-2014 - Market Trends, Marketing Spend and Sales Strategies in the Global Pharmaceutical Industry
- United Kingdom Pharmaceuticals & Healthcare Report Q1 2014
- Germany Pharmaceuticals & Healthcare Report Q1 2014
- Slovakia Pharmaceuticals & Healthcare Report Q1 2014
- Pharmaceutical Business Confidence Report Q4 2013
- Israel Pharmaceuticals & Healthcare Report Q1 2014
- Jordan Pharmaceuticals & Healthcare Report Q1 2014
- Philippines Pharmaceuticals & Healthcare Report Q1 2014
- Taiwan Pharmaceuticals & Healthcare Report Q1 2014